These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38528335)

  • 1. Chronic Pain Management in a CYP2D6 Poor Metabolizer: A Case Report for Oxycodone.
    Pednekar D; Russell J; Bardolia C; Thacker D; Amin NS
    Sr Care Pharm; 2024 Apr; 39(4):137-142. PubMed ID: 38528335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
    Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
    Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complicated pain management in a CYP450 2D6 poor metabolizer.
    Foster A; Mobley E; Wang Z
    Pain Pract; 2007 Dec; 7(4):352-6. PubMed ID: 17986163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of CYP2D6 substrates and inhibitors during pain management with analgesic opioids: Drug-drug interactions that lead to lack of analgesic effectiveness.
    Muriel J; Escorial M; Carratalá C; Margarit C; Barrachina J; López A; Gallardo E; Kringen MK; Peiró AM
    Biomed Pharmacother; 2024 Jul; 176():116882. PubMed ID: 38876046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydromorphone for cancer pain.
    Bao YJ; Hou W; Kong XY; Yang L; Xia J; Hua BJ; Knaggs R
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD011108. PubMed ID: 27727452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.
    Susce MT; Murray-Carmichael E; de Leon J
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics of oxycodone: a narrative literature review.
    Umukoro NN; Aruldhas BW; Rossos R; Pawale D; Renschler JS; Sadhasivam S
    Pharmacogenomics; 2021 Apr; 22(5):275-290. PubMed ID: 33728947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.
    Andreassen TN; Eftedal I; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
    Eur J Clin Pharmacol; 2012 Jan; 68(1):55-64. PubMed ID: 21735164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.
    Stamer UM; Zhang L; Book M; Lehmann LE; Stuber F; Musshoff F
    PLoS One; 2013; 8(3):e60239. PubMed ID: 23555934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
    Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
    Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.
    Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH
    Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioids for cancer pain - an overview of Cochrane reviews.
    Wiffen PJ; Wee B; Derry S; Bell RF; Moore RA
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012592. PubMed ID: 28683172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of the impact of Michigan's opioid prescribing legislation on discharge opioid prescribing at a single institution.
    Sadowski R; Hillaker E; Chavarria M; Khaliq F; Schwark A
    J Opioid Manag; 2022; 18(5):467-474. PubMed ID: 36226786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
    Matic M; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GAPJM; Weide JV; Wilffert B; Swen JJ; Guchelaar HJ; Deneer VHM; van Schaik RHN
    Eur J Hum Genet; 2022 Oct; 30(10):1105-1113. PubMed ID: 34267337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.
    Thomas CD; Parvataneni HK; Gray CF; Deen JT; Prieto HA; Pulido LF; Elsey AR; Elwood EN; Starostik P; Gong Y; Fillingim RB; Johnson JA; Cavallari LH
    Genet Med; 2021 Apr; 23(4):621-628. PubMed ID: 33420349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators.
    Cavallari LH; Cicali E; Wiisanen K; Fillingim RB; Chakraborty H; Myers RA; Blake KV; Asiyanbola B; Baye JF; Bronson WH; Cook KJ; Elwood EN; Gray CF; Gong Y; Hines L; Kannry J; Kucher N; Lynch S; Nguyen KA; Obeng AO; Pratt VM; Prieto HA; Ramos M; Sadeghpour A; Singh R; Rosenman M; Starostik P; Thomas CD; Tillman E; Dexter PR; Horowitz CR; Orlando LA; Peterson JF; Skaar TC; Van Driest SL; Volpi S; Voora D; Parvataneni HK; Johnson JA;
    Clin Transl Sci; 2022 Oct; 15(10):2479-2492. PubMed ID: 35899435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.